Form 4: Charles River Labs Director James C. Foster Adjusts Holdings

Charles River Laboratories director James C. Foster reported a series of transfers of common stock to various trusts on June 5, 2026, involving over 183,000 shares.

Summary

• James C. Foster, a Director at Charles River Laboratories International, Inc. (CRL), reported transactions on June 5, 2026.
• These transactions involved the transfer of common stock to various trusts.
• Specifically, 153,361 shares were transferred to a revocable trust controlled by Foster.
• An additional 20,000 shares were transferred to another revocable trust controlled by Foster.
• Furthermore, 10,000 shares held by Foster's spouse were transferred to a revocable trust controlled by his spouse.
• Following these transfers, Foster's direct beneficial ownership of common stock changed, with some shares now held indirectly through trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a significant number of shares, the transfers are to trusts controlled by the reporting person or his spouse, indicating a continuation of beneficial ownership rather than a sale or divestment.

Positives

• The reporting person is a Director at Charles River Laboratories, indicating a significant role within the company.
• The transactions were conducted under Rule 16a-13, suggesting they are exempt from certain reporting requirements and are likely part of estate or trust planning, which can be a normal part of wealth management for executives.
• The reporting person continues to hold a substantial number of shares, both directly and indirectly, indicating continued investment in the company.

Negatives

• A significant number of shares (over 183,000) have been moved from direct ownership to indirect ownership via trusts, which could be perceived as a reduction in direct control or immediate beneficial interest for the reporting person, although the trusts are controlled by him or his spouse.
• The filing does not provide specific financial details or reasons for these transfers beyond the general explanation of exempt transfers to trusts.

Risks

• While the transfers are to trusts controlled by the reporting person or his spouse, any future sale of these shares from the trusts could potentially impact the stock price if executed in large volumes.
• Changes in beneficial ownership, even if to controlled trusts, can sometimes be misinterpreted by the market, leading to short-term volatility.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it pertains to changes in beneficial ownership.

Management Comments

• Reflects the exempt transfer pursuant to Rule 16a-13 of 153,361 shares held by the reporting person to a revocable trust controlled by the reporting person.
• Reflects the exempt transfer pursuant to Rule 16a-13 of 20,000 shares held by the reporting person to a revocable trust controlled by the reporting person.
• Reflects the exempt transfer pursuant to Rule 16a-13 of 10,000 shares held by the reporting person's spouse to a revocable trust controlled by the reporting person's spouse.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for directors and officers to report changes in their holdings. Such transfers to trusts are common for estate planning and wealth management purposes and do not inherently signal a change in the executive's confidence in the company, especially when the trusts remain under their control.

Related Party Transactions

• Transfer of 153,361 shares from James C. Foster to a revocable trust controlled by James C. Foster.
• Transfer of 20,000 shares from James C. Foster to a revocable trust controlled by James C. Foster.
• Transfer of 10,000 shares from James C. Foster's spouse to a revocable trust controlled by James C. Foster's spouse.

Stakeholder Impact

• Shareholders: The transfers do not represent a sale of shares to the public, so immediate market impact is unlikely. However, changes in direct vs. indirect ownership are noted.
• Management: Standard reporting for executive wealth management and estate planning.
• Creditors/Suppliers: No direct impact expected from this type of filing.

Next Steps

• Continue to monitor future Form 4 filings from James C. Foster and other insiders for any changes in beneficial ownership that may indicate shifts in their investment sentiment.
• Observe the trading activity of Charles River Laboratories' common stock for any unusual patterns following this disclosure.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Beneficial Ownership, Stock Transfer, Trust, Director, SEC Filing, Securities Exchange Act